- Fiscal 2024 net revenue of $159.8 million
- 17.6% year-over-year growth in Organigram's recreational
shipped sales in Fiscal 2024
- Q4 Fiscal 2024 adjusted gross margin1 of 37%
- Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net
revenue
- Q4 Fiscal 2024 cash flow from operations of $8.9 million
- Became Canada's largest cannabis company by market share
following the acquisition of Motif Labs subsequent to year end
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the
“Company” or “Organigram”), a leading licensed producer (“LP”) of
cannabis, announced its results for the fourth quarter and twelve
months ended September 30, 2024 (“Q4 Fiscal 2024” or “Fiscal
2024”). All financial information in this press release is
expressed in Canadian dollars (“$”).
Comparable Periods: The Company's results for Q4 Fiscal
2024 and Fiscal 2024 reflect the three-month and 12-month periods
ended September 30, 2024. The Company’s change in year-end effected
in fiscal year 2023 (“Fiscal 2023”) resulted in its reporting
periods of for the fourth quarter of 2023 and Fiscal 2023 having 4
months and 13 months, respectively. For comparative purposes and to
more accurately reflect period-over-period performance, the
Company's financial results and period-over-period comparisons are
presented in this news release for the unaudited and unreviewed
three-month period ended September 30, 2023 (“Comparative Q4 Fiscal
2023”), and the unaudited and unreviewed 12-month period ended
September 30, 2023 (“Comparative Fiscal 2023”), unless otherwise
indicated.
FOURTH QUARTER AND FISCAL 2024 HIGHLIGHTS
- Fiscal 2024 adjusted EBITDA1 increased 55% compared to
Comparative Fiscal 2023.
- Q4 Fiscal 2024 net revenue increased 10% compared to Q3 Fiscal
2024 and 22% versus Comparative Q4 2023.
- Q4 Fiscal 2024 adjusted EBITDA1 increased to $5.9 million, from
$3.5 million in Q3 Fiscal 2024, and from $0.1 million in
Comparative Q4 Fiscal 2023.
- Moved from the #2 spot in the Canadian market as of year-end3
to the #1 LP by market share post-acquisition of Motif Labs Ltd
(“Motif”) subsequent to year-end4.
- Achieved adjusted gross margin2 of 37% in Q4 Fiscal 2024 due to
efficiency increases across cultivation, manufacturing, and
distribution.
- Realized $9.1 million in annual cost savings through extensive
efficiency initiatives in Fiscal 2024.
- Achieved sequential quarterly growth in international sales
throughout Fiscal 2024 and increased international customer base
from five to eight supply partners in Fiscal 2024.
- Completed $21 million strategic investment in German cannabis
leader Sanity Group GmbH (“Sanity Group”), and expanded strategic
investments in the US, leveraging dedicated Jupiter investment
pool.
- EU-GMP (European Union good manufacturing practice) audit
completed at the Company's Moncton facility in November, 2024, and
awaiting certification, which is expected to support growing demand
from international markets and contribute to increases in
international revenue with strong margins.
- In Fiscal 2024, the Company enhanced its balance sheet by
closing two tranches of the $124.6 million follow-on investment by
BT DE Investments Inc., a wholly-owned subsidiary of British
American Tobacco p.l.c. (“BAT”) for gross proceeds of $83.1
million, with the final $41.5 million tranche expected to close in
February 2025. Separately, the Company completed a $28.8 million
overnight marketed offering in April 2024.
“Fiscal 2024 was a transformative year where our entire team
delivered on multiple fronts,” said Beena Goldenberg, Chief
Executive Officer. “We received significant funding from BAT when
capital for the cannabis industry was scarce. We made smart,
strategic investments, including into seed-based technology and
automation, which is increasing efficiency. We have also expanded
our international footprint through a $21 million investment in
Sanity Group, a leading German cannabis company, as well as through
several new supply agreements to provide products to patients in
Australia and the UK. As we integrate recently-acquired Motif into
the Organigram ecosystem, we head into Fiscal 2025 as Canada's #1
LP and we are very excited for the next phase of our growth plans
focused on efficiency, consumer-centric innovation, and
international expansion.”
FISCAL 2024 FINANCIAL OVERVIEW
- Net revenue increased 6% to $159.8 million from $150.4 million
in Comparative Fiscal 2023 primarily due to an increase in
recreational and international revenue.
- Cost of sales decreased to $111.4 million, compared to $128.1
million in Comparative Fiscal 2023, due to operational
efficiencies.
- Gross margin before fair value changes to biological assets,
inventories sold, and other charges increased to $48.5 million from
$22.3 million in Comparative Fiscal 2023, primarily due to higher
net revenue and operational efficiencies.
- Adjusted gross margin5 was $53.9 million, or 34% of net
revenue, compared to $37.3 million, or 25% in Comparative Fiscal
2023. The improvement was primarily due to increased sales in
higher margin categories, lower cultivation and post-harvesting
costs, and higher international sales.
- Selling general and administrative (“SG&A”) expenses
decreased to $65.7 million, compared to $67.7 million in
Comparative Fiscal 2023. Annual SG&A expenses as a percent of
net revenue decreased to 41% from 45%, due to cost savings
initiatives, including lower technology costs associated with the
implementation of a new ERP system, professional fees and lower
depreciation resulting from impairment charges recorded in Fiscal
2023.
- Adjusted EBITDA6 increased 55% to $8.4 million in Fiscal 2024,
compared to $5.4 million in Comparative Fiscal 2023 as a result of
higher recreational cannabis revenue and a higher adjusted gross
margin resulting from lower cultivation and post-harvest
costs.
- Net loss was $45.4 million, compared to net loss of $247.0
million in Comparative Fiscal 2023. The decrease in net loss from
the comparative period is primarily due to higher adjusted gross
margins and lower impairment loss that was recorded in Comparative
Fiscal 2023.
- Net cash provided by (used in) operating activities before
working capital changes was $3.9 million, compared to $(52.1)
million in Comparative Fiscal 2023. The improvement was primarily
attributed to a reduced net loss.
FOURTH QUARTER FISCAL 2024 FINANCIAL OVERVIEW
- Net revenue increased 22% to $44.7 million, from $36.7 million
in Comparative Q4 Fiscal 2023 primarily due to higher recreational
cannabis sales and higher international sales.
- Cost of sales decreased to $30.9 million, from $34.3 million in
Comparative Q4 Fiscal 2023, primarily as a result of operational
efficiencies and lower inventory provisions in Q4 Fiscal 2024.
- Gross margin before fair value changes to biological assets,
inventories sold, and other charges increased to $13.8 million from
$2.4 million in Comparative Q4 Fiscal 2023, driven by a higher
proportion of international sales with stronger margins, lower cost
of sales achieved through operating efficiencies, and reduced
inventory provisions.
- Adjusted gross margin was $16.5 million, or 37% of net revenue,
compared to $7.2 million, or 20%, in Comparative Q4 Fiscal 2023,
largely due to lower cost of sales and higher recreational and
international sales.
- SG&A expenses decreased to $14.3 million from $15.8 million
in Comparative Q4 Fiscal 2023, primarily due to lower technology
costs including implementation expenses for a new ERP system, as
well as reduced insurance costs, professional fees, and
depreciation and amortization.
- Adjusted EBITDA was $5.9 million compared to $0.1 million in
Comparative Q4 Fiscal 2023, primarily attributable to higher net
flower revenue, lower general and administrative expenses and the
increase in adjusted gross margins.
- Net loss was $5.4 million, compared to a net loss of $26.6
million in Comparative Q4 Fiscal 2023. The decrease in net loss
from the comparative period is primarily due to higher adjusted
gross margins5 and lower impairment losses in the current
quarter.
- Net cash provided by (used in) operating activities before
working capital changes was $8.9 million, compared to $(8.5) in
Comparative Q4 Fiscal 2023.
“We are pleased with the growth we achieved every quarter in
Fiscal 2024, ending the year on a high note with respect to net
revenue and adjusted EBITDA,” said Greg Guyatt, Chief Financial
Officer. “Efficiency improvements in our operations supported our
strong adjusted gross margin in the quarter. Our operational
improvements, combined with our recent acquisition of Motif, has
laid the foundation for continued growth in Fiscal 2025.”
Canadian Recreational Market Introduction Highlights
As an industry leader and pure-play cannabis company, Organigram
remains committed to delivering consumer focused innovations and
products to the Canadian market. Some recent notable highlights
include:
SHRED X Tiger blood Heavies - Infused
pre-rolls
Big Bag O' Buds Midnight M'mosa & First
Class Funk - Large format flower
Big Jar of Joints - 56 x 0.5g joints
SHRED Captain Kush - 7g milled flower
Edison Sonics - 2 x 5mg THC FASTTM
Nanoemulsion gummies
Research and Product Development
Product Development Collaboration (“PDC”)
- Organigram and BAT continue to work together through their PDC
on new work streams to develop innovative technologies in the
edible, vape and beverage categories in addition to new disruptive
inhalation formats aimed at addressing the biggest consumer pain
points that exist in the category today.
- The first commercialized product resulting from PDC research is
the Edison Sonics - gummies utilizing Organigram's Fast Acting
Soluble Technology (FASTTM), clinically validated through a PK
study to have up to 50% faster onset and nearly twice as high peak
cannabinoid concentration compared to traditional gummies.
Follow-on Strategic Investment from BAT and creation of
“Jupiter” Investment Pool
- On November 6, 2023, Organigram announced a $124.6 million
follow-on investment from BAT and the creation of “Jupiter”, a
strategic investment pool designed to expand Organigram’s
geographic footprint and capitalize on emerging growth
opportunities.
- The first two $41.5 million tranches of the follow-on
investment were closed in calendar 2024, with the final $41.5
million tranche expected to close in February 2025.
International Investments & Jupiter Strategic Investment
Pool
- As described above, the Company made its first significant
European strategic investment to expand its presence in the
European cannabis market with a $21 million investment in Sanity
Group, a leading German cannabis company.
- Jupiter has deployed capital to two international strategic
investments: Steady State LLC (d/b/a Open Book Extracts) in the
U.S. and Sanity Group in Germany.
- Prior to the establishment of Jupiter, Organigram had already
made a strategic investment in U.S.-based Phylos Bioscience Inc., a
leading in seed-based technology. The Company achieved 9% of
cannabis harvest from seeds in Q4 Fiscal 2024 and 22% by the end of
calendar 2024, contributing to a reduction in cultivation costs and
increased cultivation capacity. The Company expects to further
leverage lower-cost seed-based technology by targeting
approximately 20% of harvests from seeds in fiscal year 2025, with
monthly fluctuations between 15% and 30% depending on the cultivar
requirements.
- Organigram is exploring additional U.S. and international
investment opportunities that align with the Company's strategy to
establish itself as a global leader and enhance profitability, with
the goal of delivering long-term shareholder value.
International Sales
- In Fiscal 2024, the Company signed three new international
supply agreements with customers in Germany, Australia and the
UK.
- The Company now has supply agreements with nine partners in
Germany, the UK, Australia and Israel, and is evaluating additional
global partnership opportunities.
- The Company's EU-GMP audit was completed in November. If
successful in obtaining certification, the Company expects its
international sales to increase.
Balance Sheet and Liquidity
- On September 30, 2024, the Company had cash and short-term
investments, including restricted cash, of $133.4 million compared
to $51.8 million at September 30, 2023. The increase is primarily a
result of closing the first two $41.5 million tranches of the BAT
follow-on investment of $124.6 million, and the Company's $28.8
million overnight marketed offering closed in April, 2024. The
company expects the final $41.5 million tranche to close in
February 2025.
- Subsequent to year end, the Company's cash on hand decreased by
approximately $55 million due to the acquisition of Motif,
consisting of cash consideration of $50 million and approximately
$5 million in transaction costs.
- Organigram believes its capital position is strong and that
there is sufficient liquidity available to meet our strategic and
operational objectives in fiscal 2025.
Select Balance Sheet Metrics (in
$000s)
SEPTEMBER 30,
2024
SEPTEMBER 30,
2023
% Change
Cash, restricted cash & short-term
investments
133,426
51,757
158
%
Biological assets & inventories
82,524
80,953
2
%
Other current assets
86,996
49,596
75
%
Accounts payable & accrued
liabilities
47,097
20,007
135
%
Working capital
208,897
133,545
56
%
Property, plant & equipment
96,231
99,046
(3
)%
Long-term debt
25
79
(68
)%
Total assets
407,860
298,455
37
%
Total liabilities
101,871
26,832
280
%
Shareholders’ equity
305,989
271,623
13
%
CAPITAL STRUCTURE
in $000s
SEPTEMBER 30,
2024
SEPTEMBER 30,
2023
Current and long-term debt
25
79
Shareholders’ equity
305,989
271,623
Total debt and shareholders’ equity
306,014
271,702
in 000s
Outstanding common shares
108,585
103,801
Options
2,691
2,830
Warrants
4,236
4,236
Top-up rights
7,079
2,035
Restricted share units
2,974
881
Performance share units
1,117
261
Total fully-diluted shares
126,682
114,044
Outstanding basic and fully diluted share count as at December
18, 2024 is as follows:
in 000s
DECEMBER 18,
2024
Outstanding common shares
108,585
Options
2,684
Warrants
4,236
Top-up rights
8,466
Restricted share units
3,711
Performance share units
1,846
Total fully-diluted shares
129,528
Select Key Financial Metrics
(in $000s unless otherwise indicated)
Fiscal 2024
Comparative
Fiscal 20233
% Change
Gross revenue
247,177
217,354
14
%
Excise taxes
(87,336
)
(66,957
)
30
%
Net revenue
159,841
150,397
6
%
Cost of sales
111,390
128,142
(13
)%
Gross margin before fair value changes to
biological assets & inventories sold
48,451
22,255
118
%
Realized loss on fair value on inventories
sold and other inventory charges
(52,078
)
(56,187
)
(7
)%
Unrealized gain on changes in fair value
of biological assets
51,151
68,981
(26
)%
Gross margin
47,524
35,049
36
%
Adjusted gross margin1
53,934
37,268
45
%
Adjusted gross margin %1
34
%
25
%
36
%
Selling (including marketing), general
& administrative expenses2
65,721
67,661
(3
)%
Adjusted EBITDA1
8,416
5,405
56
%
Net loss
(45,440
)
(247,002
)
82
%
Net cash provided by (used in) operating
activities before working capital changes
(11,085
)
(33,699
)
(67
)%
Net cash provided by (used in) operating
after working capital changes
3,872
(52,134
)
107
%
1 Adjusted gross margin, adjusted gross
margin % and Adjusted EBITDA are non-IFRS financial measures not
defined by and do not have any standardized meaning under IFRS;
please refer to “Non-IFRS Financial Measures” in this press release
for more information.
2 Excluding non-cash share-based
compensation.
3 Comparative Fiscal 2023 results are for
the unaudited twelve month period beginning October 1, 2022 and
ending September 30, 2023.
Select Key Financial Metrics
(in $000s unless otherwise indicated)
Q4-2024
Comparative
Q4 F'232
% Change
Gross revenue
69,877
56,179
24
%
Excise taxes
(25,179
)
(19,481
)
29
%
Net revenue
44,698
36,698
22
%
Cost of sales
30,907
34,321
(10
)%
Gross margin before fair value changes to
biological assets & inventories sold
13,791
2,377
480
%
Realized loss on fair value on inventories
sold and other inventory charges
(15,365
)
(15,901
)
(3
)%
Unrealized gain (loss) on changes in fair
value of biological assets
18,790
21,751
(14
)%
Gross margin
17,216
8,227
109
%
Adjusted gross margin1
16,543
7,161
131
%
Adjusted gross margin %1
37
%
20
%
85
%
Selling (including marketing), general
& administrative expenses2
14,300
15,787
(9
)%
Adjusted EBITDA1
5,860
58
10003
%
Net loss
(5,433
)
(26,595
)
80
%
Net cash provided by (used in) operating
activities before working capital changes
1,191
(12,957
)
(109
)%
Net cash provided by (used in) operating
activities
8,893
(8,469
)
(205
)%
1 Adjusted gross margin, adjusted gross
margin % and Adjusted EBITDA are non-IFRS financial measures not
defined by and do not have any standardized meaning under IFRS;
please refer to “Non-IFRS Financial Measures” in this press release
for more information.
2 Comparative Q4 Fiscal 2023 results are
for the unaudited three month period beginning July 1, 2023 and
ending September 30, 2023
ADJUSTED GROSS MARGIN AND ADJUSTED EBITDA
RECONCILIATION
Adjusted Gross Margin Reconciliation
(in $000s unless otherwise indicated)
Q4-2024
Comparative
Q4-20231
Fiscal 2024
Comparative
Fiscal 2023
Net revenue
$
44,698
$
36,698
$
159,841
$
150,397
Cost of sales before adjustments
28,155
29,537
105,907
113,129
Adjusted gross margin
16,543
7,161
53,934
37,268
Adjusted gross margin %
37
%
20
%
34
%
25
%
Less:
Provisions of inventories and biological
assets
2,043
532
4,657
5,678
Provisions to net realizable value
709
4,252
826
9,334
Incremental fair value component on
inventories sold from acquisitions
—
—
—
—
Unabsorbed overhead
—
—
—
—
Gross margin before fair value
adjustments
13,791
2,377
48,451
22,256
Gross margin % (before fair value
adjustments)
31
%
6
%
30
%
15
%
Add:
Realized loss on fair value on inventories
sold and other inventory charges
(15,365
)
(15,901
)
(52,078
)
(56,187
)
Unrealized gain on changes in fair value
of biological assets
18,790
21,751
51,151
68,981
Gross margin
17,216
8,227
47,524
35,050
Gross margin %
39
%
22
%
30
%
23
%
1 Comparative Q4 Fiscal 2023 results are
for the unaudited three month period beginning July 1, 2023 and
ending September 30, 2023
Adjusted EBITDA Reconciliation
(in $000s unless otherwise indicated)
Q4-2024
Comparative
Q4-20231
Fiscal 2024
Comparative
Fiscal 2023
Net loss as reported
(5,433
)
(26,595
)
(45,440
)
(247,002
)
Add/(deduct):
Financing costs, net of investment
income
(960
)
(652
)
(3,311
)
(3,423
)
Income tax recovery
30
(2,279
)
—
(3,812
)
Depreciation, amortization, and (gain)
loss on disposal of property, plant and equipment (per statement of
cash flows)
3,097
3,294
11,446
23,959
Normalization of depreciation add-back due
to changes in depreciable assets resulting from impairment
charges
—
3,037
757
3,037
Impairment of intangible assets
—
6,951
—
44,856
Impairment of property, plant and
equipment
—
11,918
—
165,255
Share of loss (gain) from investments in
associates and impairment loss (recovery) from loan receivable
4,895
(51
)
5,284
829
Realized loss on fair value on inventories
sold and other inventory charges
15,365
15,901
52,078
56,187
Unrealized gain on change in fair value of
biological assets
(18,790
)
(21,751
)
(51,151
)
(68,981
)
Share-based compensation (per statement of
cash flows)
1,093
797
7,182
5,008
Legal provisions (recoveries), government
subsidies, insurance recoveries and other non-operating expenses
(income)
(184
)
(407
)
(176
)
(482
)
Share issuance costs allocated to
derivative warrant liabilities and change in fair value of
derivative liabilities, other financial assets and contingent
consideration
1,911
(53
)
8,605
(6,158
)
ERP implementation costs
465
1,588
1,636
7,175
Transaction costs
74
505
915
1,437
Provisions (recoveries) and net realizable
value adjustments related to inventory and biological assets
2,752
4,784
5,483
15,012
Research and development expenditures, net
of depreciation
1,545
2,601
10,869
12,038
Provision for Canndoc expected credit
losses
—
470
4,239
470
Adjusted EBITDA
$
5,860
$
58
$
8,416
$
5,405
1 Comparative Q4 Fiscal 2023 results are
for the unaudited three month period beginning July 1, 2023 and
ending September 30, 2023
FOURTH QUARTER AND FULL YEAR FISCAL 2024 CONFERENCE
CALL
The Company will host a conference call to discuss its results
with details as follows: Date: December 18, 2024 Time: 8:00 am
Eastern Time
To register for the conference call, please use this link:
https://conferencingportals.com/event/XWQpOvKk
To ensure you are connected for the full call, we suggest
registering a day in advance or at minimum 10 minutes before the
start of the call. After registering, a confirmation will be sent
through email, including dial in details and unique conference call
codes for entry. Registration is open through the live call.
To access the webcast:
https://events.q4inc.com/attendee/990999128
A replay of the webcast will be available within 24 hours after
the conclusion of the call at https://www.organigram.ca/investors
and will be archived for a period of 90 days following the
call.
Non-IFRS Financial Measures
This news release refers to certain financial performance
measures (including adjusted gross margin, adjusted gross margin %
and adjusted EBITDA) that are not defined by and do not have a
standardized meaning under International Financial Reporting
Standards (“IFRS”) as issued by the International Accounting
Standards Board. Non-IFRS financial measures are used by management
to assess the financial and operational performance of the Company.
The Company believes that these non-IFRS financial measures, in
addition to conventional measures prepared in accordance with IFRS,
enable investors to evaluate the Company’s operating results,
underlying performance and prospects in a similar manner to the
Company’s management. As there are no standardized methods of
calculating these non-IFRS measures, the Company’s approaches may
differ from those used by others, and accordingly, the use of these
measures may not be directly comparable. Accordingly, these
non-IFRS measures are intended to provide additional information
and should not be considered in isolation or as a substitute for
measures of performance prepared in accordance with IFRS. Adjusted
EBITDA is a non-IFRS measure that the Company defines as net income
(loss) before: financing costs, net of investment income; income
tax expense (recovery); depreciation, amortization, reversal of/or
impairment, (gain) loss on disposal of property, plant and
equipment (per the consolidated statement of cash flows);
share-based compensation (per the consolidated statement of cash
flows); share of loss from investments in associates and impairment
loss (recovery) from loan receivable; unrealized loss (gain) on
changes in fair value of contingent consideration; change in fair
value of derivative liabilities; expenditures incurred in
connection with research & development activities (net of
depreciation); unrealized (gain) loss on changes in fair value of
biological assets; realized loss on fair value on inventories sold
and other inventory charges; provisions and impairment of
inventories and biological assets; provisions (recoveries) to net
realizable value of inventories; government subsidies and insurance
recoveries; legal provisions (recoveries); incremental fair value
component of inventories sold from acquisitions; ERP implementation
costs; transaction costs; and share issuance costs. Adjusted EBITDA
is intended to provide a proxy for the Company’s operating cash
flow and derive expectations of future financial performance for
the Company, and excludes adjustments that are not reflective of
current operating results.
Adjusted gross margin is a non-IFRS measure that the Company
defines as net revenue less cost of sales, before the effects of
(i) unrealized gain (loss) on changes in fair value of biological
assets; (ii) realized fair value on inventories sold and other
inventory charges; (iii) provisions (recoveries) and impairment of
inventories and biological assets; (iv) provisions to net
realizable value. Adjusted gross margin % is calculated by dividing
adjusted gross margin by net revenue. Management believes that
these measures provide useful information to assess the
profitability of our operations as it represents the normalized
gross margin generated from operations and excludes the effects of
non-cash fair value adjustments on inventories and biological
assets, which are required by IFRS.
The most directly comparable measure to adjusted EBITDA,
calculated in accordance with IFRS is net income (loss) and
beginning on page 9 of this press release is a reconciliation to
such measure. The most directly comparable measure to adjusted
gross margin calculated in accordance with IFRS is gross margin
before fair value changes to biological assets and inventories sold
and beginning on page 8 of this press release is a reconciliation
to such measure.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and
TSX listed company whose wholly-owned subsidiaries include
Organigram Inc., a licensed cultivator or cannabis and manufacturer
of cannabis-derived goods in Canada, and recently acquired Motif
Labs Ltd., a licensed cannabis processor.
Organigram is focused on producing high-quality, indoor-grown
cannabis for patients and adult recreational consumers in Canada,
as well as developing international business partnerships to extend
the Company’s global footprint. Organigram has also developed a
portfolio of legal adult-use recreational cannabis brands,
including Edison, Big Bag O’ Buds, SHRED, Monjour and Trailblazer.
Organigram operates facilities in Moncton, New Brunswick and
Lac-Supérieur, Québec, with a dedicated manufacturing facility in
Winnipeg, Manitoba. As a result of the acquisition of Motif Labs
Ltd. on December 6, 2024, the Company now operates two additional
cannabis processing facilities in Southwestern Ontario; one in
Aylmer and the other in London. The facility in Aylmer houses
best-in-class CO2 and Hydrocarbon extraction capabilities, and is
optimized for formulation refinement, post-processing of minor
cannabinoids, and pre-roll production. The facility in London will
be optimized for labelling, packaging, and national fulfillment.
The Company is regulated by the Cannabis Act and the Cannabis
Regulations (Canada).
This news release contains forward-looking information.
Forward-looking information, in general, can be identified by the
use of forward-looking terminology such as “outlook”, “objective”,
“may”, “will”, “could”, “would”, “might”, “expect”, “intend”,
“estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”,
“schedule” or “forecast” or similar expressions suggesting future
outcomes or events. They include, but are not limited to,
statements with respect to expectations, projections or other
characterizations of future events or circumstances, and the
Company’s objectives, goals, strategies, beliefs, intentions,
plans, estimates, forecasts, projections and outlook, including
statements relating to the Company’s future performance, the
Company’s positioning to capture additional market share and sales
including international sales, expectations for consumer demand,
expected increase in SKUs, expected improvement to gross margins
before fair value changes to biological assets and inventories,
expectations regarding adjusted gross margins, adjusted EBITDA and
net revenue in Fiscal 2024 and beyond, expectations regarding
cultivation capacity, the Company’s plans and objectives including
around the PDC, the closing of the final tranche of the follow-on
investment from BAT, availability and sources of any future
financing, availability of cost efficiency opportunities, the
increase in the number of retail stores, the ability of the Company
to fulfill demand for its revitalized product portfolio with
increased staffing, expectations relating to greater capacity to
meet demand due to increased capacity at the Company’s facilities,
expectations around lower product cultivation costs, the ability to
achieve economies of scale and ramp up cultivation, expectations
pertaining to the increase of automation and reduction in reliance
on manual labour, expectations around the launch of higher margin
dried flower strains, expectations around market and consumer
demand and other patterns related to existing, new and planned
product forms; timing for launch of new product forms, ability of
those new product forms to capture sales and market share,
estimates around incremental sales and more generally estimates or
predictions of actions of customers, suppliers, partners,
distributors, competitors or regulatory authorities; statements
regarding the future of the Canadian and international cannabis
markets and, statements regarding the Company’s future economic
performance. These statements are not historical facts but instead
represent management beliefs regarding future events, many of
which, by their nature are inherently uncertain and beyond
management control. Forward-looking information has been based on
the Company’s current expectations about future events.
This news release contains information concerning our industry
and the markets in which we operate, including our market position
and market share, which is based on information from independent
third-party sources. Although we believe these sources to be
generally reliable, market and industry data is inherently
imprecise, subject to interpretation and cannot be verified with
complete certainty due to limits on the availability and
reliability of raw data, the voluntary nature of the data gathering
process, and other limitations and uncertainties inherent in any
statistical survey or data collection process. We have not
independently verified any third-party information contained
herein.
Forward-looking information involves known and unknown risks,
uncertainties and other factors that may cause actual events to
differ materially from current expectations. These risks,
uncertainties and factors include: general economic factors;
receipt of regulatory approvals or consents and any conditions
imposed upon same and the timing thereof; the Company's ability to
meet regulatory criteria which may be subject to change; change in
regulation including restrictions on sale of new product forms;
change in stock exchange listing practices; the Company's ability
to manage costs, timing and conditions to receiving any required
testing results and certifications; results of final testing of new
products; timing of new retail store openings being inconsistent
with preliminary expectations; changes in governmental plans
including those related to methods of distribution and timing and
launch of retail stores; timing and nature of sales and product
returns; customer buying patterns and consumer preferences not
being as predicted given this is a new and emerging market;
material weaknesses identified in the Company’s internal controls
over financial reporting; the completion of regulatory processes
and registrations including for new products and forms; market
demand and acceptance of new products and forms; unforeseen
construction or delivery delays including of equipment and
commissioning; increases to expected costs; competitive and
industry conditions; change in customer buying patterns; and
changes in crop yields. These and other risk factors are disclosed
in the Company's documents filed from time to time under the
Company’s issuer profile on the Canadian Securities Administrators’
System for Electronic Document Analysis and Retrieval+ (“SEDAR”) at
www.sedarplus.ca and reports and other information filed with or
furnished to the United States Securities and Exchange Commission
(“SEC”) from time to time on the SEC’s Electronic Document
Gathering and Retrieval System (“EDGAR”) at www.sec.gov, including
the Company’s most recent MD&A and AIF. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this news release. The Company
disclaims any intention or obligation, except to the extent
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Forward looking information is subject to risks and
uncertainties that are addressed in the “Risk Factors” section of
the MD&A dated December 18, 2024 and there can be no assurance
whatsoever that these events will occur.
____________________________________ 1 Adjusted gross margin is
a non-IFRS financial measure not defined by and does not have any
standardized meaning under IFRS; please refer to “Non-IFRS
Financial Measures” in this press release for more information. 2
Adjusted EBITDA is a non-IFRS financial measure not defined by and
does not have any standardized meaning under IFRS; please refer to
“Non-IFRS Financial Measures” in this press release for more
information. 3 As of September 30, 2024 - Multiple sources (Hifyre,
Weedcrawler, OCS wholesale sales and e-commerce orders shipped
data, provincial boards data and internal sales data) 4 Source:
Hifyre (all provinces other than QC, NB and NS), Weedcrawler (QC),
and Board Data (NB, NS, PE), R3M Oct 30 5 Adjusted gross margin is
a non-IFRS financial measure not defined by and does not have any
standardized meaning under IFRS; please refer to “Non-IFRS
Financial Measures” in this press release for more information. 6
Adjusted EBITDA is a non-IFRS financial measure not defined by and
does not have any standardized meaning under IFRS; please refer to
“Non-IFRS Financial Measures” in this press release for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241218938796/en/
For Investor Relations enquiries, please contact:
Max Schwartz, Director of Investor Relations
investors@organigram.ca
For Media enquiries, please contact:
Megan McCrae, Senior Vice President, Global Brands and Corporate
Affairs megan.mccrae@organigram.ca
Organigram (NASDAQ:OGI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Organigram (NASDAQ:OGI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024